CAJ | 학술논문

胰升糖素样肽1(GLP-1)药物在2型糖尿病患者的血糖控制中具有重要作用。此外,GLP-1药物还具有一定的心血管保护效应,其可改善血管内皮功能,缓解肥胖、高血糖、血脂异常、高血压等心血管危险因素,延缓动脉粥样硬化的发生和发展,改善心肌缺血-再灌注损伤和心力衰竭。因此,GLP-1药物在心血管疾病发生发展的不同阶段和环节中可能具有保护作用。
이승당소양태1(GLP-1)약물재2형당뇨병환자적혈당공제중구유중요작용。차외,GLP-1약물환구유일정적심혈관보호효응,기가개선혈관내피공능,완해비반、고혈당、혈지이상、고혈압등심혈관위험인소,연완동맥죽양경화적발생화발전,개선심기결혈-재관주손상화심력쇠갈。인차,GLP-1약물재심혈관질병발생발전적불동계단화배절중가능구유보호작용。
[Summary] Glucagon-like peptide-1 ( GLP-1 ) agents play important roles in glycemic control in type 2 diabetes. Moreover, these agents also show various protective effects on cardiovascular system. GLP-1 agents improve vascular endothelial function, ameliorate the risk factors of cardiovascular disease including obesity, hyperglycemia, dyslipidemia and hypertension, delay the occurrence and progression of atherosclerosis, and protect against cardiac ischemia-reperfusion injury and heart failure. Therefore, GLP-1 agents may have beneficial effects on cardiovascular diseases at different stages and in multiple aspects.